2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Targeted Oncology
Targeted oncology, a promising field within cancer research, focuses on treatments tailored to individual patients based on their genetic makeup, tumor characteristics, and other factors. This personalized approach offers the potential for more effective and less toxic therapies compared to traditional treatments. Targeted therapies often involve drugs that specifically target molecules involved in cancer growth and progression, such as certain proteins or genetic mutations. Advancements in genomics and molecular biology have facilitated the development of these therapies, allowing oncologists to better match treatments to the unique molecular profiles of patients' tumors. As research in targeted oncology continues to evolve, it holds great promise for improving outcomes and quality of life for cancer patients.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China